BARBIERI, FEDERICA
 Distribuzione geografica
Continente #
EU - Europa 11.376
Totale 11.376
Nazione #
IT - Italia 11.376
Totale 11.376
Città #
Genova 8.444
Genoa 1.120
Rapallo 997
Vado Ligure 781
Bordighera 33
Totale 11.375
Nome #
Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects 182
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma 175
New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells 167
Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm 157
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 153
Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells 153
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors 153
Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. 149
Chemokines and chemokine receptors: New actors in neuroendocrine regulations 146
Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells 143
17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease 139
In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity 139
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 137
SDF1 controls pituitary cell proliferation through the activation of ERK1/2 and the Ca2+-dependent cytosolic tyrosine kinase, Pyk2. 136
Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current 135
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets 135
Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma 134
Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds 133
Adiponectin as Novel Regulator of Cell Proliferation in Human Glioblastoma 131
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures 126
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? 125
Antisense oligonucleotides as therapeutic agents. 125
Endometrial stem cells and human reproductive failure 124
Inhibition of chloride intracellular channel 1 (CLIC1) as biguanide class-effect to impair human glioblastoma stem cell viability 123
The phosphotyrosine phosphatase PTPh mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2 122
Molecular pharmacology of malignant pleural mesothelioma: Challenges and perspectives from preclinical and clinical studies 122
Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of Phidianidine A as a new CXCR4 ligand exhibiting antagonist activity 121
Different Effects of Human Umbilical Cord Mesenchymal Stem Cells on Glioblastoma Stem Cells by Direct Cell Interaction or Via Released Soluble Factors 121
Glioblastoma cancer stem cells: response to epidermal growth factor receptor kinase inhibitors 120
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 120
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas 120
Differential efficacy of SSTR1, 2 and 5 agonists in the inhibition of C6 glioma growth in nude mice 119
Persistent increase of D-aspartate in D-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay 118
Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. 117
Primary Cultures from Human GH-secreting or Clinically Non-functioning Pituitary Adenomas 117
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures 117
Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity 116
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study 115
1,4-bis(1-naphtyl)-2,3-dinitro-1,3 butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance. 115
An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease 114
The use of antisense oligodeoxynucleotides (aODNs) in immunopharmacology. 110
Expression of cyclin D1 correlates with malignancy in human ovarian tumours 110
Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature 110
Different response of human glioma tumor-initiating cells to EGFR kinase inhibitors. 109
Isolation of stem-like cells from spontaneous feline mammary carcinomas: phenotypic characterization and tumorigenic potential 109
The chemokine SDF1/CXCL12: a novel autocrine/paracrine factor involved in pituitary adenoma development 108
Differential role of EGF and bFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensitivity 108
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells 108
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies 107
Mutual influence of ROS, pH and CLIC1 membrane protein in the regulation of G1/S phase progression in human glioblastoma stem cells 107
Synthesis and biological activity of gold and tin compounds in ovarian cancer cells 106
The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells 106
Control of cyclin D1 expression by antisense oligonucleotides in three ovarian cancer cell lines. 105
Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity 105
Somatostatin receptor 1, 2 and 5 activation leads to C6 glioma growth arrest in vitro and in vivo: analysis of the intracellular pathways involved 104
Chronic lymphocytic leukemic (CLL) B cells express the HGF receptor (C-MET) and are supported in their survival by HGF-producing mesenchymal stromal cell 104
Goat anti-human GM-CSF recognizes canine GM-CSF 104
Ruta graveolens water extract inhibits cell-cell network formation in human umbilical endothelial cells via MEK-ERK1/2 pathway 103
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 103
Novel Sigma Binding Site Ligands as Inhibitors of Cell Proliferation in Breast Cancer 102
Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. 101
Canine osteosarcoma cell lines contain stem-like cancer cells: Biological and pharmacological characterization 101
Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract 100
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment 100
The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation 99
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation 99
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 98
CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis 97
Somatostatin and somatostatin receptors 1, 2 and 5 selective agonists inhibit C6 glioma cell growth in vitro and in vivo: Analysis of activated intracellular pathways 96
null 94
Antiproliferative effect of DNA polymerase antisense oligodeoxynucleotides on breast cancer cells. 94
CXC receptors and chemokines expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation 94
Thymidine Labelling Index as prognostic factor in resected non-small cell lung cancer. 92
Chemosensitivity of glioblastoma cells during treatment with the organo-tin compound triethyltin (IV) lupinylsulfide hydrochloride. 92
Emerging Role of Cellular Prion Protein in the Maintenance and Expansion of Glioma Stem Cells 91
Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target 88
17{beta}-ESTRADIOL PROMOTES BREAST CANCER CELL PROLIFERATION INDUCING SDF-1-MEDIATED EGFR TRANSACTIVATION: REVERSAL BY GEFITINIB PRE-TREATMENT. 87
Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives 86
null 85
Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells 83
Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells 81
In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5 81
A liposomal formulation for inflammation targeting 80
Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in Ovarian tumors 78
Control of gene expression by triplex forming oligonucleotides in human live cells. 76
Antitumor activity of a new o rally active organotin compound: a preliminare study in murine tumor models 76
Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt 76
Somatostatin receptors 1, 2 and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro, via a PTPh-dependent inhibition of ERK1/2. 75
Feasibility of Thymidine Labelling Index on fine needle aspirates from breast cancer: comparison with surgical samples. 73
Amyloid-beta Protein Precursor Regulates Phosphorylation and Cellular Compartmentalization of Microtubule Associated Protein Tau 71
Diethylstilbestrol (DES) and recombinant human growth (rhGH) as modulator of breast cancer proliferative activity. 71
Cytotoxicity in vitro and preliminary antitumor activity in vivo of a novel organotin compound 70
Inhibition of DNA polymerase a expression and cell growth, a possible triple helix machanism. 69
CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumor meningothelial cells in vitro 68
Expression of somatostatin receptors mRNA in human meningiomas and their implication in in vitro antiproliferative activity 68
Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies 67
Expression of CXC chemokine receptors and ligands in human meningiomas: SDF1 activation of CXCR4 activates ERK1/2 and stimulates meningioma cell proliferation 65
Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity 63
Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferaton and migration. 62
Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. 61
Totale 10.750
Categoria #
all - tutte 35.261
article - articoli 33.457
book - libri 0
conference - conferenze 1.501
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 303
Totale 70.522


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.450 0 0 0 0 267 335 447 192 280 481 347 101
2020/2021888 55 77 81 59 102 58 46 57 68 137 89 59
2021/20221.381 55 124 73 165 35 102 95 310 66 111 58 187
2022/20231.210 108 82 14 128 147 223 1 106 209 16 149 27
2023/2024897 49 85 21 103 55 192 76 50 41 29 70 126
2024/2025851 111 180 100 243 217 0 0 0 0 0 0 0
Totale 11.687